ClinConnect ClinConnect Logo
Search / Trial NCT06250998

Prediction of Abdominal Aortic Aneurysm Shrinkage After Stent-placement With Artificial Intelligence

Launched by RIJNSTATE HOSPITAL · Feb 1, 2024

Trial Information

Current as of August 19, 2025

Recruiting

Keywords

Aaa Aneurysm Shrinkage Evar Aneurysm Remodeling Artificial Intelligence Ai

ClinConnect Summary

This clinical trial is looking at how certain factors can help predict whether an abdominal aortic aneurysm (AAA) will shrink after a stent is placed. An AAA is when the main artery in your belly becomes enlarged, which can be dangerous. The researchers want to develop a model using artificial intelligence to better understand what leads to successful treatment outcomes one year after the stent placement.

To be eligible for this study, participants must be at least 18 years old and have undergone a specific type of procedure called elective infrarenal endovascular aneurysm repair (EVAR) for an unruptured AAA. They should have had a successful procedure and be using certain approved stent devices. Participants will need to have follow-up imaging done at least a year after their procedure to help evaluate the results. This study is currently recruiting and welcomes all genders. If you join, you can expect to contribute to important research that may improve future treatments for AAA.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years;
  • Elective, initially technically successful (as described by the ESVS guidelines11), infrarenal EVAR for unruptured infrarenal AAA;
  • Implanted endograft is a Gore Excluder, Medtronic Endurant, Cook Zenith, Cordis Incraft, Endologix AFX, Jotec E-Tegra, or Vascutek Anaconda endograft;
  • Follow-up of the AAA of at least one year with imaging of the same modality as the preoperative imaging;
  • Axial reconstructions of preoperative CT angiography available, preferably in the arterial phase and with 3 mm or smaller slice thickness.
  • Exclusion Criteria:
  • Patients with ruptured or symptomatic AAA;
  • Patients that were treated with fenestrated or branched endografts, iliac branched devices, non-CE marked devices within trial setting, other endografts (EVAS cases) or chimney procedures;
  • Acute procedures;
  • Reintervention before one year follow-up;
  • Revision cases after previous open or endovascular aneurysm repair of an AAA;

About Rijnstate Hospital

Rijnstate Hospital is a leading healthcare institution based in the Netherlands, dedicated to providing high-quality patient care and advancing medical research. With a strong emphasis on innovation and collaboration, Rijnstate Hospital actively engages in clinical trials to explore new treatment options and improve patient outcomes across various medical fields. The hospital's multidisciplinary approach integrates the expertise of healthcare professionals, researchers, and academic partners, ensuring rigorous scientific methodologies and adherence to ethical standards. Committed to enhancing the health and well-being of the communities it serves, Rijnstate Hospital plays a pivotal role in the advancement of medical knowledge and the development of effective therapies.

Locations

Arnhem, , Netherlands

Enschede, , Netherlands

Groningen, , Netherlands

Amsterdam, , Netherlands

Arnhem, Non Us/Canada, Netherlands

Stockholm, , Sweden

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported